Myocardial Fibrosis
47
8
10
20
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.1%
1 terminated out of 47 trials
95.2%
+8.7% vs benchmark
17%
8 trials in Phase 3/4
10%
2 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (47)
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Echocardiography Findings in Patients With Myocardial Fibrosis and Severe Aortic Stenosis
A Health Coach-Led Digital Lifestyle Intervention (HEALDI)
High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
Effects of Aortic Valve Replacement on Myocardial T1 Values in Severe Aortic Valve Stenosis
Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
⁶⁸Ga-FAPI PET/CT for Cardiac Fibrosis in Heart Failure
Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance
Ultrahypofractionation and Normal Tissue Toxicity
MRI of Myocardial Infarction
Quantification of Myocardial Fibrosis in Aortis Stenosis
Fibrosis Assessment in Myocardial Infarction-associated Ventricular Aneurysm
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction
Myocardial Perfusion and Fibrosis in Cancer Survivors
An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images
PROFILE-MI - The FAPI Fibrosis Study
Mechanism of Decompensation Evaluation - Aortic Stenosis